Seroatlas · Human Serome Atlas

SARS2

Serine--tRNA ligase, mitochondrial

Also known as: FLJ20450, mtSerRS, SARS, SARSM, SerRSmt, SERS, SYS, SYSM_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9NP81
Gene
SARS2
Ensembl
ENSG00000104835
Chromosome
19
Canonical length
518 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Vesicles,Mitochondria
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene encodes the mitochondrial seryl-tRNA synthethase precursor, a member of the class II tRNA synthetase family. The mature enzyme catalyzes the ligation of Serine to tRNA(Ser) and participates in the biosynthesis of selenocysteinyl-tRNA(sec) in mitochondria. The enzyme contains an N-terminal tRNA binding domain and a core catalytic domain. It functions in a homodimeric form, which is stabilized by tRNA binding. This gene is regulated by a bidirectional promoter that also controls the expression of mitochondrial ribosomal protein S12. Both genes are within the critical interval for the autosomal dominant deafness locus DFNA4 and might be linked to this disease. Multiple transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

Canonical amino-acid sequenceUniProt

518 residues, UniProt reviewed canonical sequence.

>Q9NP81|SARS2
     1  MAASMARRLW PLLTRRGFRP RGGCISNDSP RRSFTTEKRN RNLLYEYARE GYSALPQLDI
    61  ERFCACPEEA AHALELRKGE LRSADLPAII STWQELRQLQ EQIRSLEEEK AAVTEAVRAL
   121  LANQDSGEVQ QDPKYQGLRA RGREIRKELV HLYPREAQLE EQFYLQALKL PNQTHPDVPV
   181  GDESQARVLH MVGDKPVFSF QPRGHLEIGE KLDIIRQKRL SHVSGHRSYY LRGAGALLQH
   241  GLVNFTFNKL LRRGFTPMTV PDLLRGAVFE GCGMTPNANP SQIYNIDPAR FKDLNLAGTA
   301  EVGLAGYFMD HTVAFRDLPV RMVCSSTCYR AETNTGQEPR GLYRVHHFTK VEMFGVTGPG
   361  LEQSSQLLEE FLSLQMEILT ELGLHFRVLD MPTQELGLPA YRKFDIEAWM PGRGRFGEVT
   421  SASNCTDFQS RRLHIMFQTE AGELQFAHTV NATACAVPRL LIALLESNQQ KDGSVLVPPA
   481  LQSYLGTDRI TAPTHVPLQY IGPNQPRKPG LPGQPAVS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SARS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.3
Highest tissue expression
18 nTPM

Expression across tissuesHPA

Tissue

  • liver: 18 nTPM
  • adrenal gland: 17 nTPM
  • skeletal muscle: 17 nTPM
  • kidney: 17 nTPM
  • pancreas: 16 nTPM
  • esophagus: 14 nTPM

Single-cell type

  • late spermatids: 7.7 nCPM
  • distal convoluted tubule cells: 5.2 nCPM
  • proximal tubule cells: 5 nCPM
  • renal collecting duct intercalated cells: 5 nCPM
  • astrocytes: 4.1 nCPM
  • erythrocyte progenitors: 4.1 nCPM

Immune cell

  • myeloid DC: 25 nTPM
  • memory CD8 T-cell: 15 nTPM
  • intermediate monocyte: 14 nTPM
  • gdT-cell: 14 nTPM
  • NK-cell: 14 nTPM
  • non-classical monocyte: 14 nTPM

Brain region

  • cerebral cortex: 9.7 nTPM
  • white matter: 8.8 nTPM
  • pons: 8.6 nTPM
  • medulla oblongata: 7.4 nTPM
  • basal ganglia: 6.9 nTPM
  • cerebellum: 6.9 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SARS2.

Disease | AllUniProt

Conditions SARS2 is implicated in, by any mechanism.

Disease | GeneticClinVar

5 pathogenic / likely-pathogenic of 412 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.93
gnomAD pLI
0
gnomAD missense Z
0.25
DepMap mean gene effect
-0.62
DepMap dependency class
common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SARS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SARS2 as an antibody target. Whether an autoantibody or antibody against SARS2 could matter depends on whether native SARS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SARS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SARS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SARS2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...